Intrinsic Value of S&P & Nasdaq Contact Us

Embecta Corp. EMBC NASDAQ

NASDAQ Global Select • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
61/100
3/7 Pass
SharesGrow Intrinsic Value
$30.67
+224.2%
Analyst Price Target
$22.50
+137.8%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Embecta Corp. (EMBC) trades at a trailing P/E of 3.7, forward P/E of 3.4. Trailing earnings yield is 27.39%, forward earnings yield 29.76%. PEG 0.17 (Peter Lynch undervalued ≤1.0).

Criteria proven by this page:

  • VALUE (90/100, Pass) — P/E is below market average (3.7); PEG ≤ 1.0 — Peter Lynch undervalued (0.17); analyst target implies upside (+137.8%); earnings yield beats bond yields (27.39%).
  • Forward P/E 3.4 (down from trailing 3.7) — analysts expect earnings to grow, which would improve the valuation.
  • PEG Ratio 0.17 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
  • Trailing Earnings Yield 27.39% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 29.76% as earnings recover.
  • Analyst consensus target $22.50 (+137.8% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 61/100 with 3/7 criteria passed.

SharesGrow 7-Criteria Score
61/100
SG Score
View full scorecard →
VALUE
90/100
Price-to-Earnings & upside
Proven by this page
~
FUTURE
52/100
Analyst consensus
→ Forecast
PAST
100/100
→ Income
HEALTH
75/100
Debt-to-Equity & liquidity
→ Health
~
MOAT
53/100
→ Income
GROWTH
15/100
→ Income
~
INCOME
45/100
→ Income

Valuation Snapshot — EMBC

Valuation Multiples
P/E (TTM)3.7
Forward P/E3.4
PEG Ratio0.17
Forward PEG0.05
P/B Ratio-0.83
P/S Ratio0.48
EV/EBITDA4.9
Per Share Data
EPS (TTM)$2.39
Forward EPS (Est.)$2.82
Book Value / Share$-10.51
Revenue / Share$18.52
FCF / Share$3.53
Yields & Fair Value
Earnings Yield27.39%
Forward Earnings Yield29.76%
Dividend Yield6.87%
SharesGrow IV$30.67 (+224.2%)
Analyst Target$22.50 (+137.8%)

Historical Valuation

Year P/E (TTM) PEG Ratio P/B Ratio P/S Ratio Dividend Yield
2019 6.2 0.00 4.64 2.42 -
2020 6.3 -5.94 4.68 2.47 -
2021 6.4 -2.54 4.49 2.29 -
2022 7.3 -0.16 -1.84 1.45 0.52%
2023 12.2 -0.18 -1.05 0.77 3.99%
2024 10.5 1.00 -1.12 0.73 4.19%
2025 8.6 0.42 -1.26 0.76 4.25%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2019 $7.58 $1.11B $432M 39%
2020 $7.50 $1.09B $427.6M 39.4%
2021 $7.31 $1.17B $414.8M 35.6%
2022 $3.92 $1.13B $223.6M 19.8%
2023 $1.22 $1.12B $70.4M 6.3%
2024 $1.34 $1.12B $78.3M 7%
2025 $1.62 $1.08B $95.4M 8.8%

Analyst Estimates

Year EPS (Avg) EPS Range Revenue (Avg) Revenue Range Analysts
2026 $2.82 $2.81 – $2.82 $1.07B $1.07B – $1.07B 3
2027 $2.88 $2.84 – $2.91 $1.07B $1.07B – $1.07B 3
2028 $2.98 $2.35 – $3.48 $1.08B $1.07B – $1.08B 3
2029 $2.96 $2.95 – $2.97 $966.97M $964.59M – $969.18M 1
2030 $3.06 $3.05 – $3.07 $940.52M $938.21M – $942.67M 1
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message